Identification and angiogenic role of the novel tumor endothelial marker CLEC14A - PubMed (original) (raw)
. 2012 Jan 19;31(3):293-305.
doi: 10.1038/onc.2011.233. Epub 2011 Jun 27.
R K Swain, X Zhuang, H Vorschmitt, G Reynolds, S Durant, J F J Beesley, J M J Herbert, H Sheldon, M Andre, S Sanderson, K Glen, N-T Luu, H M McGettrick, P Antczak, F Falciani, G B Nash, Z S Nagy, R Bicknell
Affiliations
- PMID: 21706054
- DOI: 10.1038/onc.2011.233
Identification and angiogenic role of the novel tumor endothelial marker CLEC14A
M Mura et al. Oncogene. 2012.
Abstract
Tumor endothelial markers (TEMs) that are highly expressed in human tumor vasculature compared with vasculature in normal tissue hold clear therapeutic potential. We report that the C-type lectin CLEC14A is a novel TEM. Immunohistochemical and immunofluorescence staining of tissue arrays has shown that CLEC14A is strongly expressed in tumor vasculature when compared with vessels in normal tissue. CLEC14A overexpression in tumor vessels was seen in a wide range of solid tumor types. Functional studies showed that CLEC14A induces filopodia and facilitates endothelial migration, tube formation and vascular development in zebrafish that is, CLEC14A regulates pro-angiogenic phenotypes. CLEC14A antisera inhibited cell migration and tube formation, suggesting that anti-CLEC14A antibodies may have anti-angiogenic activity. Finally, in endothelial cultures, expression of CLEC14A increased at low shear stress, and we hypothesize that low shear stress due to poor blood flow in the disorganized tumor vasculature induces expression of CLEC14A on tumor vessels and pro-angiogenic phenotypes.
Similar articles
- Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro.
Ki MK, Jeoung MH, Choi JR, Rho SS, Kwon YG, Shim H, Chung J, Hong HJ, Song BD, Lee S. Ki MK, et al. Oncogene. 2013 Nov 28;32(48):5449-57. doi: 10.1038/onc.2013.156. Epub 2013 May 6. Oncogene. 2013. PMID: 23644659 Free PMC article. - An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours.
Robinson J, Whitworth K, Jinks E, Nagy Z, Bicknell R, Lee SP. Robinson J, et al. J Pathol Clin Res. 2020 Oct;6(4):308-319. doi: 10.1002/cjp2.176. Epub 2020 Jul 21. J Pathol Clin Res. 2020. PMID: 32696621 Free PMC article. - Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
Kim TK, Park CS, Jang J, Kim MR, Na HJ, Lee K, Kim HJ, Heo K, Yoo BC, Kim YM, Lee JW, Kim SJ, Kim ES, Kim DY, Cha K, Lee TG, Lee S. Kim TK, et al. Mol Oncol. 2018 Mar;12(3):356-372. doi: 10.1002/1878-0261.12169. Epub 2018 Jan 26. Mol Oncol. 2018. PMID: 29316206 Free PMC article. - C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.
Khan KA, McMurray JL, Mohammed F, Bicknell R. Khan KA, et al. FEBS J. 2019 Sep;286(17):3299-3332. doi: 10.1111/febs.14985. Epub 2019 Jul 29. FEBS J. 2019. PMID: 31287944 Free PMC article. Review. - Vascular Endothelial FSH Receptor, a Target of Interest for Cancer Therapy.
Ghinea N. Ghinea N. Endocrinology. 2018 Sep 1;159(9):3268-3274. doi: 10.1210/en.2018-00466. Endocrinology. 2018. PMID: 30113652 Review.
Cited by
- Type-H endothelial cell protein Clec14a orchestrates osteoblast activity during trabecular bone formation and patterning.
Neag G, Lewis J, Turner JD, Manning JE, Dean I, Finlay M, Poologasundarampillai G, Woods J, Sahu MA, Khan KA, Begum J, McGettrick HM, Bellantuono I, Heath V, Jones SW, Buckley CD, Bicknell R, Naylor AJ. Neag G, et al. Commun Biol. 2024 Oct 11;7(1):1296. doi: 10.1038/s42003-024-06971-3. Commun Biol. 2024. PMID: 39394430 Free PMC article. - Group XIV C-type lectins: emerging targets in tumor angiogenesis.
Yee EJ, Vigil I, Sun Y, Torphy RJ, Schulick RD, Zhu Y. Yee EJ, et al. Angiogenesis. 2024 May;27(2):173-192. doi: 10.1007/s10456-024-09907-x. Epub 2024 Mar 12. Angiogenesis. 2024. PMID: 38468017 Free PMC article. Review. - A tumor-associated endothelial signature score model in immunotherapy and prognosis across pan-cancers.
Chen S, Zhang L, Huang M, Liang Y, Wang Y. Chen S, et al. Front Pharmacol. 2023 Aug 31;14:1190660. doi: 10.3389/fphar.2023.1190660. eCollection 2023. Front Pharmacol. 2023. PMID: 37719845 Free PMC article. - Benzo[a]pyrene Exposure Reduces Cell-Type Diversity and Stimulates Sex-Biased Damage Pathways in End Organs of Lupus-Prone Mice.
Zhu R, Kennicott K, Liang Y. Zhu R, et al. Int J Mol Sci. 2023 Mar 24;24(7):6163. doi: 10.3390/ijms24076163. Int J Mol Sci. 2023. PMID: 37047136 Free PMC article. - DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer.
Sigin VO, Kalinkin AI, Nikolaeva AF, Ignatova EO, Kuznetsova EB, Chesnokova GG, Litviakov NV, Tsyganov MM, Ibragimova MK, Vinogradov II, Vinogradov MI, Vinogradov IY, Zaletaev DV, Nemtsova MV, Kutsev SI, Tanas AS, Strelnikov VV. Sigin VO, et al. Cancers (Basel). 2023 Mar 6;15(5):1630. doi: 10.3390/cancers15051630. Cancers (Basel). 2023. PMID: 36900421 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases